Evaluation of antitumor activity of rubomycin deposited in absorbable polymeric microparticles
An experimental dosage form of rubomycin is developed: the drug is incorporated in absorbable polymeric (polyhydroxybutyrate) matrix in the form of microparticles. Antitumor efficiency of this rubomycin dosage form was studied in laboratory mice with transplanted Ehrlich ascitic carcinoma. Rubomycin deposited in polymeric microparticles exhibited pronounced antitumor activity, inhibited the proliferative activity of Ehrlich ascitic carcinoma, and improved survival of mice with tumors. This dosage form of the drug can be used for local injections.
Key Wordsmicroencapsulation rubomycin absorbable polymers polyhydroxybutyrate Ehrlich’s ascitic carcinoma
Unable to display preview. Download preview PDF.
- 1.F. I. Ataullakhanov, T. V. Batasheva, and V. M. Vitvitskii, Antibiot. Khimioter., 39, No. 9–10, 26–29 (1993).Google Scholar
- 2.T. G. Volova, V. I. Sevast’yanov, and E. I. Shishatskaya, Polyhydroxylalcanoates: Biodegraded Polymers for Medicine [in Russian], Ed. V. I. Shumakov, Krasnoyarsk (2006).Google Scholar
- 3.A. M. Genin, A. E. Il’in, A. S. Kaplanskii, et al., Aviakosm. Ekol. Med., 35, No. 4, 14–20 (2001).Google Scholar
- 4.BIOPLASTOTAN Trademark, Registration Certificate No. 315652, Federal Institute of Patent Expert Evaluations, application No. 2006703271/50, priority of 15.02.06. MKTU Classes: 01, 05, 10.Google Scholar
- 5.E. I. Shishatskaya, A. V. Zhemchugova, and T. G. Volova, Antibiot. Khimioter., Nos. 2–3, 3–14 (2005).Google Scholar
- 6.E. I. Shishatskaya and A. Goreva, Perspektivnye Materialy, No. 4, 65–70 (2006).Google Scholar